{"url_path":"/sec/rmtg/10-k/2026/item-13","section_key":"item-13","section_title":"Item 13 **","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1760026/0001213900-26-056841-index.html","accession_number":"0001213900-26-056841","cik":"0001760026","ticker":"RMTG","issuer_name":"Regenerative Medical Technology Group Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1760026/0001213900-26-056841-index.html","primary_entity_key":"0001760026","primary_entity_name":"Regenerative Medical Technology Group Inc."},"word_count":421,"has_tables":true,"body_markdown":"**ITEM 13.**\n**CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.**\n\n \n\nOther than\nas disclosed below or the transactions described under the heading “Executive Compensation,” there have been no transactions\ninvolving the Company since the beginning of the last fiscal year, or any currently proposed transactions, in which the Company was or\nis to be a participant and the amount involved exceeds $120,000 or one percent of the average of the Company’s total assets at year-end\nfor the last two completed fiscal years, and in which any related person had or will have a direct or indirect material interest.\n\n \n\nThe Company’s corporate registered office\nis 433 Plaza Real Suite, 275, Boca Raton, Florida 33432. The online virtual office lease is for a month-to-month term at $89.00 per month.\nThe Company has no physical office leases that required implementation of ASU 842 in the year ended December 31, 2025, and 2024 to assets\nand liabilities.\n\n \n\nBenito Novas’ brother, sister and nephew\nprovide marketing/administrative and training/R&D services to Global Stem Cells Group and were paid $342,153 in the aggregate as consultants\nduring the year ended December 31, 2025, and $266,857 in the aggregate for the year ended December 31, 2024.\n\n**  **\n\n33\n\n \n\n**Director Independence**\n\n \n\nAs of the\ndate of this Annual Report, the Company’s Board of Directors consists of David Christensen, who also serves as Chief Executive Officer.\nThe Board has determined that Mr. Christensen is not independent under the independence standards applicable to companies listed on The\nNasdaq Stock Market or the NYSE (although the Company’s common stock is quoted on the OTC Pink marketplace and is not subject to\nthese listing standards). Due to the Company’s current size, stage of development, and capital structure (including the super-voting\nrights of the Series AA Preferred Stock held by Mr. Christensen and Benito Novas), the Board has not yet established separate committees\n(such as an audit committee, compensation committee, or nominating committee) or appointed independent directors. The Board intends to\nevaluate the addition of independent directors and the formation of appropriate committees as the Company’s operations and governance\nneeds evolve.\n\n \n\nAll related-party\ntransactions, including those described above, are subject to review and approval (or ratification) by the Board of Directors (or a designated\ncommittee) in accordance with the Company’s policies and applicable laws to ensure they are fair, reasonable, and in the best interests\nof the Company and its stockholders. The Board considers all relevant factors, including the nature of the relationship, the terms of\nthe transaction, prevailing market rates, and any potential conflicts of interest."}